Influence of Oral Probiotics on Anxiety and Depression in Adolescents After Non-cardiac and Non-gastrointestinal Surgeries: A Prospective, Double-blind, Placebo-controlled Study

June 6, 2026 updated by: Henan Provincial People's Hospital
This study intends to conduct a prospective, double-blind, randomized, controlled trial. Adolescents aged 12-17 years old and American Society of Anesthesiologists (ASA) physical status I and II are selected as subjects. Oral probiotics is used as intervention before surgery, vital signs data, serum IL-1, IL-6, BDNF,5-HT and other inflammatory indicators are collected before surgery and after non-cardiac and non-gastrointestinal surgeries, and the incidence and degree of anxiety and depression are evaluated after non-cardiac and non-gastrointestinal surgeries. To determine the effect of esketamine on reducing anxiety and depression in adolescents after non-cardiac and non-gastrointestinal surgeries, and to provide an effective clinical basis for accelerating the rehabilitation of adolescents after non-cardiac and non-gastrointestinal surgeries.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Henan
      • Zhengzhou, Henan, China, 450000
        • Henan Provincial People's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 8 years ≤ age ≤17 years;
  • Patients who plan to undergo elective surgery under general anesthesia, and the operation time is 1-2 hours;
  • ASA grade I-II
  • The body mass index falls within the normal range, which is 18.5 - 23.9 kg/m2.

Exclusion Criteria:

  • The patient has psychological disorders, including but not limited to bipolar affective disorder.
  • Eating disorder
  • No informed consent form
  • Due to certain serious diseases, one needs to take medication for a long period of time.
  • Personality disorder
  • Has undergone or needs to undergo gastrointestinal surgery
  • Have taken antibiotics or probiotics within the past 8 weeks
  • Pure vegetarian diet

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Continuous oral administration of probiotics(Bifidobacterium Tetra-Strain Live Bacteria Tablets)
Selincon
Continuous oral administration of probiotics
Placebo Comparator: Take a placebo, which looks no different from a probiotic agent
Take a placebo, which looks no different from a probiotic agent

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety scale scores after surgery during 2 month
Time Frame: 2 months
Hamilton Anxiety Rating Scale (HAMA):The lower the score, the better the result
2 months
Depression scale scores after surgery during 2 month
Time Frame: 2 months
Beck Depression Inventory (BDI):The lower the score, the better the result
2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 2, 2025

Primary Completion (Actual)

May 2, 2026

Study Completion (Actual)

May 2, 2026

Study Registration Dates

First Submitted

May 14, 2026

First Submitted That Met QC Criteria

June 6, 2026

First Posted (Actual)

June 10, 2026

Study Record Updates

Last Update Posted (Actual)

June 10, 2026

Last Update Submitted That Met QC Criteria

June 6, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HenanGY

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety Depression

Clinical Trials on C Group

Subscribe